Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $0.24 on Monday. The stock has a fifty day moving average price of $0.31 and a 200 day moving average price of $0.42. The stock has a market cap of $16.89 million, a PE ratio of -0.75 and a beta of 0.35. Brainstorm Cell Therapeutics has a 1 year low of $0.13 and a 1 year high of $0.79.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). During the same period last year, the company posted ($0.27) EPS. As a group, equities research analysts predict that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.